loader image
Saturday, October 18, 2025
92.7 F
McAllen
- Advertisement -

New Eye Cancer Therapy Shown to Target Cancer Cells, Spare Vision

Translate to Spanish or other 102 languages!

A study presented at AAO 2021, the 125th annual meeting of the American Academy of Ophthalmology, shows that it may be an effective first-line therapy for early-stage choroidal melanoma. Image for illustration purposes.
A study presented at AAO 2021, the 125th annual meeting of the American Academy of Ophthalmology, shows that it may be an effective first-line therapy for early-stage choroidal melanoma. Image for illustration purposes.

Mega Doctor News

- Advertisement -

By American Academy of Ophthalmology (AAO)

Newswise — NEW ORLEANS, La. – Nov. 15, 2021 – Choroidal melanoma is a rare cancer that affects the back of the eye. If the tumor grows, it can cause the retina to detach, leading to vision loss. And if it spreads to other parts of the body, it can be fatal. There are no approved drugs that can stop its spread, and the available treatment options commonly lead to serious vision loss or loss of the eye. But a new laser-activated nanoparticle promises to target and destroy the cancer cells and preserve vision. A study presented at AAO 2021, the 125th annual meeting of the American Academy of Ophthalmology, shows that it may be an effective first-line therapy for early-stage choroidal melanoma.

AU-011 (belzupacap sarotalocan) is a viral-like nanoparticle that is injected into the eye, and then activated with an ophthalmic laser. The nanoparticles are modeled on the human papillomavirus and bind specifically to heparin-sulfated proteoglycans expressed by ocular melanoma cells. After being activated by an ophthalmic laser, the nanoparticles disrupt the tumor cell membrane, which kills the cancer cells, leaving healthy surrounding tissue unharmed. It also activates the immune system to create long lasting anti-tumor immunity.

- Advertisement -

Data from a Phase 1b/2 trial showed a significant reduction in tumor growth over the 12-month study (-0.445 mm/yr, p=0.018), while tumor control was achieved in 60 percent of patients. At the same time, 73 percent maintained their visual acuity (best corrected visual acuity loss <15 letters). Among 56 treated subjects, two with juxtafoveal tumors had treatment-related serious adverse events of vision loss. Adverse events, Intraocular inflammation and IOP increase, were transient and clinically manageable in most subjects.

“The final safety and efficacy data from the 12-month Phase 1b/2 trial presented today, along with the Phase 2 SC data, provide a high level of confidence for the advancement of AU-011 to the pivotal program in patients with small choroidal melanoma,” said Carol Shields, MD, Chief of the Ocular Oncology Service at Wills Eye Hospital and Professor of Ophthalmology at Thomas Jefferson University. “I believe AU-011 may offer patients a safe, effective first-line therapy for early-stage choroidal melanoma that preserves vision, a critical component in patients’ quality of life often neglected with today’s current treatment options.”

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

The Human Bean’s “Coffee for a Cure” to Benefit The Renaissance Cancer Foundation, Oct. 17th

The Human Bean located at 1124 E. Nolana in McAllen is inviting coffee-lovers to "drink pink" on October 17 for their annual “Coffee for a Cure” breast cancer giveback event. All food and beverage proceeds on that day will benefit the Renaissance Cancer Foundation, marking The Human Bean’s largest fundraiser of the year.

2025 DHR Health Fashion Show & Gala Honoring Heroic Patients

The Edinburg Conference Center at Renaissance was filled with emotion, gratitude, and hope on Wednesday, October 15, 2025, as DHR Health hosted its 2025 Fashion Show & Gala Honoring Heroic Patients. The annual event celebrated breast cancer survivors and highlighted the importance of breast reconstruction awareness, education, and innovation in women’s health care.

The Harmful Effects of Alcohol on the Brain

Millions of people drink alcohol, and while many may know the harm it can cause to their liver, some may be surprised to know it can be just as damaging to the brain.

STC’s Chapa Turns Curiosity into Purpose

At just 19-years-old, STC Psychological Science student Gianna Chapa has already built a foundation for her future that reflects both determination and heart.
- Advertisement -
×